Introduction
The long-term benefits of organ transplantation are hindered by graft rejection (1) (2) (3) (4) (5) , a detrimental process driven by alloreactive T cells that recognize donor MHC antigens via the direct, indirect, and semidirect pathways of allorecognition (3, 6) . Current immunosuppressive regimens target the direct pathway and reduce acute allograft rejection (7) but are associated with severe side-effects (8) and do not effectively prevent chronic rejection (2, 9) ; thus, the half-life of allografts remains limited to 10-15 years (10, 11) .
Thymus-derived regulatory T cells (tTregs) are immunosuppressive T cells with a fundamental role in the maintenance of tolerance in vivo (12) (13) (14) (15) . These cells are characterized in humans as CD4 + CD25
hi CD127 lo and constitutively express the transcription factor forkhead-box protein 3 (FOXP3) (7, 12, 16) . In rodent models, Tregs significantly prolong the survival of skin (17) (18) (19) and heart (4) allografts and in humans, correlations between the proportion of Tregs within allografts and graft survival have been observed (20) (21) (22) . With the safety of Treg therapy having been demonstrated in the contexts of graft-versus-host disease (GvHD) (23) (24) (25) (26) and type I diabetes (27, 28) , we are conducting Phase I/II clinical trials to investigate the therapeutic potential of adoptive polyclonal Treg therapy to promote tolerance in kidney (The ONE Study: NCT02129881) and liver (ThRIL: NCT02166177) transplant recipients (29, 30) .
However, we (4, 17, 19, 31) and others (32, 33) have demonstrated in animal models that allospecific Tregs are superior to polyclonal Tregs at reducing graft rejection, upon adoptive transfer. Murine Tregs expanded with allogeneic antigen-presenting cells (APC) (direct allospecificity) and/or transduced to express an allospecific TCR (indirect allospecificity) prolonged graft survival significantly more effectively than polyclonal Tregs. These findings were confirmed using human Tregs expanded with allogeneic dendritic cells (19) and B cells (31, 34) in human skin xenograft transplant models. As such, clinical trials are assessing the safety and efficacy of Tregs with direct allospecificity in kidney (DART: NCT02188719) and liver (deLTa: NCT02188719 and NCT01624077) transplant recipients. Here, we investigated whether allospecificity may be conferred onto Tregs using chimeric antigen receptors (CAR) (35) .
CARs are synthetic fusion proteins capable of redirecting the specificity of T cells toward desired antigens. Classical CARs comprise an extracellular antigen-targeting moiety that binds a specific antigen in an MHC-independent manner and a series of customized intracellular TCR and costimulatory signaling domains. As such, CARs translate the binding of specific antigens into the activation of desired signaling cascades (36) . CARs are primarily used clinically to generate tumor antigen-specific T cells (37) (38) (39) (40) (41) (42) (43) . However, preclinical studies have shown the efficacy of CAR-modified Tregs for the treatment of colitis (16, 44, 45) and multiple sclerosis (46) . The functionality of CARs has also been demonstrated in human Tregs (47, 48) , most recently as a means of protecting against xeno-GvHD (49). However, to date, no one has demonstrated the capacity of CAR Tregs to protect from solid transplant rejection.
In this study, we applied CAR technology to generate allospecific Tregs with the aim of promoting organ transplant tolerance. We redirected human CD4  + CD25   +   CD127  lo FOXP3  + Tregs toward an MHC class I molecule  (HLA-A2) , an alloantigen that is ubiquitously expressed in an allograft, with the hypothesis that they would be more potent than polyclonal Tregs at protecting from graft rejection, upon adoptive transfer.
Materials and Methods

CAR generation
A previously described (50) HLA-A2-specific single-chain variable fragment (scFv) sequence (3PB2 V H and DPK1 V L ) was validated by immunoprecipitation (data not shown) and cloned upstream of (i) a 9E10 cMyc epitope; (ii) a human CD28 hinge/transmembrane domain; (iii) a human CD28-CD3f signaling domain; and (iv) an enhanced green fluorescent protein (eGFP) open reading frame in a second-generation pLNT/SFFV lentiviral plasmid (provided by Prof. Adrian Thrasher; UCL, London, UK). A truncated CAR (DCAR) was generated by removing the CD28-CD3f signaling domain from the full-length CAR-eGFP fusion. All plasmids were verified by sequencing (Beckman Coulter Genomics, Takeley, Essex, UK). Tregs/effector T cells (Teffs) were activated with anti-CD3/CD28 beads (1:1 bead:cell ratio; Thermo Fisher Scientific, Paisley, Renfrewshire, UK) and cultured in X-vivo TM 15 (Lonza, Slough, Berkshire, UK) supplemented with 5% human AB serum (BioSera, Uckfield East, Sussex, UK). Treg were cultured with 100 nM rapamycin (LC-Laboratories, Woburn, MA) and 1000 U/mL recombinant IL-2 (Proleukin-Novartis, Camberley, Surrey, UK), whereas Teffs were cultured with 100 U/mL IL-2 only.
Human
Flow cytometry and cell sorting
Cells were stained in phosphate-buffered saline (PBS) supplemented with 1% heat-inactivated fetal calf serum (FCS) and 5 mM EDTA (all from Thermo Fisher Scientific) using fluorescently conjugated antibodies specific for HLA-A2 (BB7.2), CD4 (OKT4), FOXP3 (PCH101), CD39 (eBioA1), CD69 (H1.2F3) (all from eBioscience, Hatfield, Hertfordshire, UK), CD25 (4E3 or 2A3), CTLA-4 (BNI3) (all from BD Biosciences, Oxford, Oxfordshire, UK) CD127 (A019D5), CCR4 (L291H4), CCR9 (L053E8), CCR10 (5688-5), CD62L (DREG-56), integrin b7 (FIB504), CLA (HECA-452), HLA-DR (all from BioLegend, London, UK), HLA-A2 (REA142) (Miltenyi-Biotec), and HLA class I (Tu149) (Thermo Fisher Scientific). Cells were stained with PE-conjugated HLA-A*0201/CINGVCWTV and HLA-B*0702/DPRRRSRNL dextramers (Immudex, Copenhagen, Denmark) provided by Dr. Marc Martinez-Llordella; KCL, London, UK. Dead cells were excluded using live/dead near-IR staining (Thermo Fisher Scientific). Intracellular staining was performed using the eBioscience Fix/Perm kit. Cells were acquired and sorted using an LSRFortessa II and FACSAria II (BD), respectively. Data were analyzed using FlowJo 7 or 10 (Tree Star, Ashland, OR).
Immortalized cell line culture
HEK293T, MCF-7, and T-47D epithelial cells were grown in DMEM-based media. B-Lymphoblastoid cell lines (B-LCL) and K562s (donated by Dr. Marc Martinez-Llordella) were grown in RPMI-based media. All culture media were supplemented with 10% heat-inactivated FCS, 100 units/mL penicillin, 100 lg/mL streptomycin, and 2 mM L-glutamine (all from Thermo Fisher Scientific). HLA-transfected K562 cultures were supplemented with 5 lg/mL neomycin (Thermo Fisher Scientific). All cells were grown at 37°C in the presence of 5% (vol/vol) CO 2 .
Lentivirus production and Treg/Teff transduction HEK293T cells were cotransfected with pLNT/SFFV-CAR-eGFP or pLNT/ SFFV-DCAR-eGFP ( Figure 1A ), pD8.91 and pCMV-VSV-G plasmids at a mass ratio of 4:3:1 using polyethylenimine (3:1 PEI:DNA wt/wt; SigmaAldrich, Gillingham, Dorset, UK). Viral supernatant was harvested 48-56 h posttransfection and lentiviral particles were concentrated using PEG-it 
Human skin xenograft transplant model
Human skin was obtained from routine surgical procedures with informed consent and ethical approval (Guy's and St. Thomas' NHS Foundation
Trust and King's College London; reference 06/Q0704/18). Donor HLA-A2 expression was determined by flow cytometry, staining skin-derived cells obtained by collagenase digestion (100 lg/mL; Sigma-Aldrich). Splitthickness skin grafts (1.5 cm 2 ) were transplanted onto 10-11-week-old recipient BRG mice as previously described (19) and mice were administered 100 lg anti-mouse Gr-1 (BioXCell, Upper Heyford, Oxfordshire, UK) intraperitoneally every 3-4 days. After 5-6 weeks ( Figure S4 ), mice were injected intravenously with 5 9 10 6 peripheral blood mononuclear cells (PBMCs) AE 1 9 10 6 Tregs. Skin grafts were harvested for histological analysis 5 weeks following PBMCs/Tregs transfer.
Histological analysis of human skin
Skin grafts were frozen in optimal cutting temperature (OCT) (Thermo Fisher Scientific). Eight-or 16-lm-thick sections were fixed in 4% paraformaldehyde, blocked with a mixture of 10% donkey serum, 0.1% fish skin gelatin, 0.1% Triton X-100, and 0. 
Statistical analysis
Data shown are mean AE SEM or mean AE SD. Statistical significance was determined using two-tailed paired Student's t-tests or analysis of variance (ANOVA) with the Tukey multiple comparison post-hoc test. p < 0.05, p < 0.01, p < 0.001, and p < 0.0001.
Results
Generation and validation of a novel HLA-A2-specific CAR A HLA-A2-specific CAR incorporating a human CD28-CD3f signaling domain was generated using a patientderived HLA-A2-specific scFv sequence (50) ( Figure 1A and B). A second-generation CAR was selected based on the superior function of these CARs relative to firstgeneration CARs (52-55) and the importance of CD28 signaling for Treg activation (56) . To investigate the importance of this signaling domain, a HLA-A2-specific CAR lacking a CD28-CD3f signaling domain (DCAR) was also generated ( Figure 1A and B). This control was selected, as opposed to a CAR containing a scrambled ectodomain, to ascertain whether the ability of the Tregs to engage HLA-A2 was sufficient to elicit protection in vivo or whether Treg activation via the CAR was also necessary.
To confirm the functionality and HLA-A2-specificity of these CARs, polyclonal CD4 + CD25 − effector T cells (Teffs) were transduced with VSV-G-pseudotyped lentiviral particles containing the CAR or the DCAR constructs with an efficiency of 40-80% (54.3-62.8 AE 11.9%; Figure 1C ). eGFP + Teffs were purified by cell sorting and cocultured overnight with confluent monolayers of MCF-7 and T-47D cells, breast cancer epithelial cells that differentially expressed HLA-A2 ( Figure 1D Tregs were enriched using good manufacturing practice (GMP)-compatible protocols (58) from the peripheral blood of healthy HLA-A2 -donors with a purity of approximately 90% (89.5 AE 4.4%, n = 16; Figure S1A ). A high proportion of the cells were FOXP3 + with a low expression of CD127 ( Figure S1B ). These cells were activated using anti-CD3/CD28 beads and expanded in the presence of 1000 U/mL recombinant human IL-2 and 100 nM rapamycin (29, 58) Figure 2B ), which facilitated in the specific recognition of a HLA-A2-based dextramer but not an irrelevant HLA-B7-based dextramer ( Figure 2C ). Furthermore, engagement of HLA-A2 was shown to specifically activate CAR Tregs but not untransduced or DCAR Tregs ( Figure 2D and Figure S2 ). Tregs can function by secreting granzyme and perforin (59, 60) . To exclude the risk of unwanted cytotoxicity, Tregs were cocultured with confluent monolayers of HLA-A2 + and HLA-A2 À epithelial cells, as previously described (Figure 1) . Unlike CAR Teffs, CAR Tregs exhibited no detectable level of cytotoxicity toward the HLA-A2 + cells ( Figure 3D ). IL-2 secretion was undetectable in all conditions analyzed (data not shown) and low levels of IFNc (221 AE 80 pg/lL; Figure 3E ) were produced by CAR Tregs cocultured with HLA-A2 + monolayers. In contrast, these cells produced significantly high levels of the immunosuppressive cytokine IL-10 (1055 AE 78 pg/lL) compared to polyclonal Tregs (not detected) and DCAR Tregs (8 AE 1 pg/lL) ( Figure 3F ), suggesting that in vivo, CAR Tregs would contribute to the establishment of an intragraft immunosuppressive milieu in HLA-A2 + allografts.
Given the importance of Treg trafficking in vivo, we investigated whether the expression of HLA-A2 by endothelial cells influenced the rate with which CAR Tregs transmigrated (61) . Relative to polyclonal Tregs, CAR and DCAR Tregs transmigrated through HLA-A2 + endothelial monolayers significantly faster than through HLA-A2 À endothelial monolayers (p = 0.042; Figure 3G ), suggesting a preferential migration into HLA-A2 + target tissues.
Overall, these results demonstrated that compared to polyclonal Tregs, donor-specific CAR Tregs exhibited a greater suppressive capacity in the presence of HLA-A2 without eliciting cytotoxic activity and transmigrated at a faster rate through HUVECs expressing HLA-A2.
CAR-mediated Treg allorecognition conferred a functional advantage in preventing skin graft rejection
We have previously demonstrated the superior efficacy of human Tregs with direct allospecificity over polyclonal Tregs at reducing alloimmune injury in a human skin xenograft transplant model (19, 31) . To investigate whether CAR Tregs elicited a similar protective role, the same model was employed ( Figure S4 ). Human skin was obtained from routine abdominal angioplasty surgery and HLA-A2 expression was determined using collagenasetreated skin explants ( Figure S5 ). BRG mice were transplanted with HLA-A2 + skin grafts and following skin engraftment, were injected with allogeneic CD25-depleted HLA-A2 − PBMCs AE autologous Tregs. Mice did not exhibit any signs of GvHD throughout the experiments (Figure S6A) . Skin grafts were explanted and analyzed histologically for changes in the skin morphology and immune cell infiltration 5 weeks post-PBMC transfer ( Figure S4B ). Cryosections were stained with hematoxylin and eosin ( Figure S6B ) or analyzed by immunofluorescence.
Significant alloimmune damage was observed in the grafts of mice that received PBMCs, as demonstrated by a high number of Ki67 + keratinocytes ( Figure 4A ), a loss of CD31 + blood vessel integrity and loss of the involucrinexpressing epidermal layer ( Figure 4B ). Grafts of mice treated with PBMCs and Tregs had comparatively fewer Ki67 + keratinocytes ( Figure 4A ), intact CD31 + blood vessels, and a defined involucrin layer (62) (Figure 4B ). Quantification of these observations demonstrated that CAR Treg treatment reduced the number of Ki67 + keratinocytes to basal levels, exhibiting significantly more protection than polyclonal Tregs (p = 0.042) ( Figure 4D ). Interestingly, in this readout of graft damage, DCAR Tregs also mediated superior protection to polyclonal Tregs, although statistical significance was not reached (p = 0.11). Conversely, when measuring damage in terms of CD31 + blood vessel integrity, CAR Tregs (CD31 + cluster size = 88.9 AE 8.5; p < 0.0001) mediated protection more effectively than both polyclonal (73.3 AE 8.7; p = 0.017) and DCAR (70.9 AE 10.1; p = 0.026) Tregs ( Figure 4E ). Mice that received PBMCs with CAR or DCAR Tregs (p < 0.0001 versus PBMCs alone) had a greater FOXP3:CD3 ratio than mice that received PBMCs with polyclonal Tregs (p = 0.019). Together, these results suggested that CAR expression facilitated preferential homing and retention of the Tregs in the HLA-A2 + allografts. This localization to the graft enabled the DCAR Tregs to elicit more protection than polyclonal Tregs, likely due to these cells being activated in a TCR-dependent manner through direct allorecognition. However, the protection offered was further improved upon by the CAR Tregs that were activated in both a TCR-dependent (direct allorecognition) and CAR-dependent manner.
In conclusion, CAR-engineered HLA-A2-specific Tregs inhibited alloimmune-mediated injury against HLA-A2 + skin allografts significantly more effectively than polyclonal or DCAR Tregs, demonstrating the increased potency of these cells in vivo and the requirement for Treg signaling to elicit this response.
Discussion
Animal models of transplantation have demonstrated that allospecific Tregs are superior to polyclonal Tregs at protecting from allograft rejection (4, 17, 19, (31) (32) (33) (34) . Here, we isolated human Tregs using GMP-compatible protocols and used CAR technology to generate donor-MHC class I-allospecific CAR Tregs, which were functionally superior to polyclonal Tregs in vitro and in a human skin xenograft transplant model. These results demonstrated a promising new direction for clinical trials that are currently assessing the safety and efficacy of polyclonal Treg therapy in kidney (The ONE Study: NCT02129881) and liver (ThRIL: NCT02166177) transplant recipients (29, 30) .
Tregs that recognize allo-MHC-peptide complexes (direct allorecognition) and/or allopeptides presented in the context of recipient MHC (indirect allospecificity) have been shown to suppress alloimmune responses more effectively than polyclonal Tregs (4, (17) (18) (19) (31) (32) (33) (34) . However, the potential of CD4 + Tregs is limited as they are MHC class II-restricted, thus activated primarily by professional APCs. CARs recognize their target antigen in an MHCindependent manner and as such, can confer specificity for donor MHC class I, an alloantigen ubiquitously expressed on tissue parenchyma throughout an allograft.
In this study, we selected HLA-A2 as a target antigen due to its comparatively high prevalence (>40%) in UK donors (63) . The scFv used to construct the HLA-A2-specific CAR cross-reacts with HLA-A28 and HLA-A68 (50) . CARs that cross-react with various HLA alleles can be used in a wide variety of donor-recipient combinations; thus we believe that generating a library of HLA class I-specific CARs using cross-reactive scFvs will allow for an efficient adaptation into the clinic. Furthermore, we demonstrated that these CARs can be efficiently delivered into human Tregs by lentiviral transduction, which is currently employed clinically to deliver CD19-specific CARs into Teffs for the treatment of CLL (37, 38) . Progress based on the CRISPR/Cas9 system may make more directed and safer gene delivery accessible in the near future (33) .
CAR Tregs demonstrably protected HLA-A2 + human skin grafts more effectively than polyclonal Tregs. However, interesting results were also obtained for the DCAR Tregs. These cells exhibited a favored migration and retention in HLA-A2 + target tissues, which enabled the elicitation of greater graft protection than polyclonal Tregs. However, in terms of CD31 + blood vessel integrity, the protection offered by the DCAR Tregs was not as great as the CAR Tregs. These findings suggested that the Treg localization was an important factor in determining the protection offered, particularly as TCRmediated direct allorecognition could facilitate activation of these cells in the graft. However, to exploit the full potential of CAR technology, a functional CAR that activated Tregs in the presence of HLA-A2 was required.
Although CARs have principally been used to generate cancer-specific Teffs, studies investigating the therapeutic potential of CAR Tregs have been performed. Very recently, the efficacy of human CAR Tregs was PBMCs AE 1 9 10 6 Tregs. Control mice received saline only. Human skin grafts were removed 5 weeks postinjection and cryopreserved sections were fixed and stained either for human CD45/Ki67/DAPI (A), CD31/involucrin/DAPI (B), or human FOXP3/human CD3/DAPI (C). Images are representative immunofluorescence stains of human skin grafts. Quantification of the number of Ki67 + keratinocytes (D), CD31 + cluster size (E), and FOXP3:CD3 ratio (F) per field of view was performed using NIS Elements and FIJI imaging software (51) . Results represent two to three mice/group where four to six fields of view were quantified per section and data are representative of two individual experiments. Significance was determined by one-way ANOVA and the Tukey multiple comparison post-hoc test where * = p < 0.05, *** = p < 0.001, and **** = p < 0.0001. ANOVA, analysis of variance; CAR, chimeric antigen receptor; DCAR, truncated chimeric antigen receptor; DAPI, 4 0 ,6-diamidino-2-phenylindole; ns, not significant; PBMCs, peripheral blood mononuclear cells; Tregs, regulatory T cells; UN-TDX, untransduced. demonstrated in the prevention of xeno-GvHD (49) . Furthermore, in preclinical models of colitis (16, 44, 45) and multiple sclerosis (46) , CAR Tregs were found to migrate to locations where their cognate antigen was expressed and suppress undesired immune responses more effectively than polyclonal Tregs. Similarly, we have shown that CAR Tregs redirected toward HLA-A2 preferentially transmigrate through alloantigen-expressing endothelial cells and exhibit a favored homing and retention in allografts. These observations suggest a clinical potential for CAR Tregs outside of the transplant field, particularly in light of ongoing clinical trials that are assessing the safety and efficacy of polyclonal Treg therapy for the treatment of type I diabetes (NCT01210664) (27) , lupus erythematosus (NCT02428309), and uveitis (NCT02494492).
In conclusion, polyclonal Treg therapy is currently being investigated clinically by us and others as a means of limiting graft rejection. However, to avoid the risk of panimmunosuppression and provide a tailored therapy, the successful generation and expansion of alloantigenspecific Tregs is required. We demonstrated that clinically applicable CAR technology may be used to generate donor antigen-specific Tregs that suppress alloimmune responses, providing a future direction for Treg therapy in the pursuit of transplant tolerance in solid organ transplantation.
Supporting Information
Additional Supporting Information may be found in the online version of this article. Small explants of human skin were tested for HLA-A2 expression by flow cytometry prior to transplantation. Cells acquired by treating explants with collagenase for 1 hour were stained with two separate HLA-A2-specific antibody clones (BB7.2 and REA142 denoted by blue and green lines, respectively). HLA-A2-expression was compared to cells stained with an isotype control, shown in solid gray. 
